Skip to content
value.today

FutureWorld: peers

Change the peers

FutureWorld beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

FutureWorld: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

FutureWorld, Actinium Pharmaceuticals, Inc., AIM ImmunoTech Inc., iBio, Inc., Inovio Pharmaceuticals, Inc., Silo Pharma, Inc., Ainos, Inc., BullFrog AI Holdings, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureFutureWorldbase
FWDG · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Actinium Pharmaceuticals, Inc.
ATNM · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
AIM ImmunoTech Inc.
AIM · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
iBio, Inc.
IBIO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Inovio Pharmaceuticals, Inc.
INO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Silo Pharma, Inc.
SILO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Ainos, Inc.
AIMD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
BullFrog AI Holdings, Inc.
BFRG · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)——$48 MOct 30, 2026 · Market data3rd of 7$6 MOct 27, 2026 · Market data5th of 7$59 MOct 9, 2026 · Market data2nd of 7$144 MOct 30, 2026 · Market data1st of 7$3 MOct 5, 2026 · Market data7th of 7$6 MOct 26, 2026 · Market data6th of 7$9 MOct 29, 2026 · Market data4th of 7$9 M7 ranked
Revenue (Better neither way: ranked highest first)$0 MFY2014 · SEC4th of 8$0 MFY2025 · SEC4th of 8$0 MFY2025 · SEC4th of 8$0 MFY2026 · SEC3rd of 8$0 MFY2025 · SEC7th of 8$0 MFY2025 · SEC7th of 8$0 MFY2025 · SEC1st of 8$0 MFY2025 · SEC1st of 8$0 M8 ranked
Net income (Higher is better)$-2 MFY2014 · SEC1st of 8$-34 MFY2025 · SEC7th of 8$-14 MFY2025 · SEC4th of 8$-33 MFY2026 · SEC6th of 8$-85 MFY2025 · SEC8th of 8$-4 MFY2025 · SEC2nd of 8$-15 MFY2025 · SEC5th of 8$-7 MFY2025 · SEC3rd of 8$-14 M8 ranked
Employees (Better neither way: ranked highest first)——25March 25, 2026 · Profile3rd of 4————317As on 2021 · Profile1st of 4——41December 31, 2025 · Profile2nd of 49December 31, 2025 · Profile4th of 4334 ranked
Margins and returns
Return on equity (Higher is better)————-167.0%FY2025 · SEC4th of 613th6th————-65.7%FY2026 · SEC1st of 635th15th-183.5%FY2025 · SEC6th of 612th5th-74.6%FY2025 · SEC2nd of 632nd14th-128.0%FY2025 · SEC3rd of 619th8th-183.1%FY2025 · SEC5th of 612th5th-147.5%6 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————534.6×price Oct 30, 2026 · Market data2nd of 698th100th71.0×price Oct 27, 2026 · Market data4th of 693rd97th591.6×price Oct 9, 2026 · Market data1st of 699th100th————46.1×price Oct 5, 2026 · Market data6th of 690th97th51.1×price Oct 26, 2026 · Market data5th of 691st97th76.3×price Oct 29, 2026 · Market data3rd of 693rd98th73.7×6 ranked
Price to book (Better neither way: ranked highest first)————6.1×price Oct 30, 2026 · Market data1st of 673rd81st————0.7×price Oct 9, 2026 · Market data5th of 612th11th6.0×price Oct 30, 2026 · Market data2nd of 672nd80th0.5×price Oct 5, 2026 · Market data6th of 67th7th0.8×price Oct 26, 2026 · Market data4th of 615th15th4.3×price Oct 29, 2026 · Market data3rd of 662nd73rd2.5×6 ranked
Free cash flow yield (Higher is better)————-51.3%price Oct 30, 2026 · Market data3rd of 518th7th————-40.2%price Oct 9, 2026 · Market data2nd of 521st9th-61.6%price Oct 30, 2026 · Market data4th of 515th6th————-75.7%price Oct 26, 2026 · Market data5th of 511th4th-10.0%price Oct 29, 2026 · Market data1st of 542nd21st-51.3%5 ranked
Financial strength
Interest cover (Higher is better)————————-14.4×FY2025 · SEC1st of 337th18th-702.8×FY2026 · SEC3rd of 33rd1st————-107.0×FY2025 · SEC2nd of 315th6th————————-107.0×3 ranked
Scorecard
Scorecard (Higher is better)——1 of 12FY2025 · Scorecard5th of 71 of 13FY2025 · Scorecard6th of 72 of 14FY2026 · Scorecard2nd of 72 of 13FY2025 · Scorecard1st of 72 of 14FY2025 · Scorecard2nd of 72 of 14FY2025 · Scorecard2nd of 71 of 13FY2025 · Scorecard6th of 714% passed7 ranked
Valuation checks (Higher is better)——0 of 3FY2025 · Scorecard4th of 70 of 4FY2025 · Scorecard4th of 71 of 5FY2026 · Scorecard2nd of 70 of 4FY2025 · Scorecard4th of 71 of 4FY2025 · Scorecard1st of 71 of 5FY2025 · Scorecard2nd of 70 of 5FY2025 · Scorecard4th of 70% passed7 ranked
Growth checks (Higher is better)——0 of 2FY2025 · Scorecard3rd of 71 of 3FY2025 · Scorecard2nd of 70 of 2FY2026 · Scorecard3rd of 71 of 2FY2025 · Scorecard1st of 70 of 2FY2025 · Scorecard3rd of 70 of 2FY2025 · Scorecard3rd of 70 of 1FY2025 · Scorecard3rd of 70% passed7 ranked
Profitability checks (Higher is better)——0 of 3FY2025 · Scorecard1st of 70 of 2FY2025 · Scorecard1st of 70 of 3FY2026 · Scorecard1st of 70 of 3FY2025 · Scorecard1st of 70 of 3FY2025 · Scorecard1st of 70 of 3FY2025 · Scorecard1st of 70 of 3FY2025 · Scorecard1st of 70% passed7 ranked
Financial health checks (Higher is better)——1 of 3FY2025 · Scorecard1st of 70 of 3FY2025 · Scorecard7th of 71 of 4FY2026 · Scorecard5th of 71 of 3FY2025 · Scorecard1st of 71 of 4FY2025 · Scorecard5th of 71 of 3FY2025 · Scorecard1st of 71 of 3FY2025 · Scorecard1st of 733% passed7 ranked
Shareholder returns checks (Higher is better)——0 of 1FY2025 · Scorecard1st of 60 of 1FY2025 · Scorecard1st of 6——0 of 1FY2025 · Scorecard1st of 60 of 1FY2025 · Scorecard1st of 60 of 1FY2025 · Scorecard1st of 60 of 1FY2025 · Scorecard1st of 60% passed6 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——16.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 72.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 758.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 733.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 718.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 72.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 74.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 716.0%7 ranked
Institutions holding (Better neither way: ranked highest first)——502026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7602026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 71112026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7152026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7247 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——-0.1 pp2026-Q2 against 2026-Q1 · 13F5th of 6+1.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 6+14.9 pp2026-Q2 against 2026-Q1 · 13F1st of 6-13.7 pp2026-Q2 against 2026-Q1 · 13F6th of 6——+0.5 pp2026-Q2 against 2026-Q1 · 13F4th of 6+2.1 pp2026-Q2 against 2026-Q1 · 13F2nd of 6+1.1 pp6 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = FutureWorld: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Actinium Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; AIM ImmunoTech Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; iBio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Inovio Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Silo Pharma, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Ainos, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; BullFrog AI Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Return on equity#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Return on equity: each company's figure and its percentile in its sector and its country
CompanyReturn on equityIn its sectorIn its country
FutureWorld———
Actinium Pharmaceuticals, Inc.-167.0%FY2025
13th percentile in Healthcaremedian -36.9%, 977 companies
6th percentile in USAmedian 4.8%, 3,580 companies
AIM ImmunoTech Inc.———
iBio, Inc.-65.7%FY2026
35th percentile in Healthcaremedian -36.9%, 977 companies
15th percentile in USAmedian 4.8%, 3,580 companies
Inovio Pharmaceuticals, Inc.-183.5%FY2025
12th percentile in Healthcaremedian -36.9%, 977 companies
5th percentile in USAmedian 4.8%, 3,580 companies
Silo Pharma, Inc.-74.6%FY2025
32nd percentile in Healthcaremedian -36.9%, 977 companies
14th percentile in USAmedian 4.8%, 3,580 companies
Ainos, Inc.-128.0%FY2025
19th percentile in Healthcaremedian -36.9%, 977 companies
8th percentile in USAmedian 4.8%, 3,580 companies
BullFrog AI Holdings, Inc.-183.1%FY2025
12th percentile in Healthcaremedian -36.9%, 977 companies
5th percentile in USAmedian 4.8%, 3,580 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$11 M$21 M$32 M$42 M201020122014201620182020202220242026Actinium Pharmaceuticals, Inc. $0 MAIM ImmunoTech Inc. $0 MiBio, Inc. $0 MInovio Pharmaceuticals, Inc. $0 MSilo Pharma, Inc. $0 MAinos, Inc. $0 MBullFrog AI Holdings, Inc. $0 M

Rank in the group

1st2nd3rd4th5th6th7th20122013201420152016201720182019202020212022202320242025FutureWorld: 4th of 4 in 2014FutureWorldActinium Pharmaceuticals, Inc.: 2nd of 4 in 2021Actinium Pharmaceuticals, Inc.: 4th of 7 in 2022Actinium Pharmaceuticals, Inc.: 4th of 7 in 2025Actinium Pharmaceuticals, AIM ImmunoTech Inc.: 3rd of 3 in 2012AIM ImmunoTech Inc.: 3rd of 3 in 2013AIM ImmunoTech Inc.: 2nd of 4 in 2014AIM ImmunoTech Inc.: 3rd of 3 in 2015AIM ImmunoTech Inc.: 3rd of 3 in 2016AIM ImmunoTech Inc.: 2nd of 4 in 2017AIM ImmunoTech Inc.: 3rd of 4 in 2018AIM ImmunoTech Inc.: 3rd of 5 in 2019AIM ImmunoTech Inc.: 3rd of 5 in 2020AIM ImmunoTech Inc.: 4th of 4 in 2021AIM ImmunoTech Inc.: 5th of 7 in 2022AIM ImmunoTech Inc.: 2nd of 5 in 2023AIM ImmunoTech Inc.: 3rd of 4 in 2024AIM ImmunoTech Inc.: 4th of 7 in 2025AIM ImmunoTech Inc.iBio, Inc.: 2nd of 3 in 2012iBio, Inc.: 2nd of 3 in 2013iBio, Inc.: 2nd of 4 in 2014iBio, Inc.: 2nd of 3 in 2015iBio, Inc.: 2nd of 3 in 2016iBio, Inc.: 3rd of 4 in 2017iBio, Inc.: 2nd of 4 in 2018iBio, Inc.: 2nd of 5 in 2019iBio, Inc.: 2nd of 5 in 2020iBio, Inc.: 1st of 4 in 2021iBio, Inc.: 3rd of 7 in 2022iBio, Inc.: 1st of 4 in 2024iBio, Inc.: 1st of 7 in 2025iBio, Inc.Inovio Pharmaceuticals, Inc.: 1st of 3 in 2012Inovio Pharmaceuticals, Inc.: 1st of 3 in 2013Inovio Pharmaceuticals, Inc.: 1st of 4 in 2014Inovio Pharmaceuticals, Inc.: 1st of 3 in 2015Inovio Pharmaceuticals, Inc.: 1st of 3 in 2016Inovio Pharmaceuticals, Inc.: 1st of 4 in 2017Inovio Pharmaceuticals, Inc.: 1st of 4 in 2018Inovio Pharmaceuticals, Inc.: 1st of 5 in 2019Inovio Pharmaceuticals, Inc.: 1st of 5 in 2020Inovio Pharmaceuticals, Inc.: 1st of 7 in 2022Inovio Pharmaceuticals, Inc.: 1st of 5 in 2023Inovio Pharmaceuticals, Inc.: 1st of 4 in 2024Inovio Pharmaceuticals, Inc.: 6th of 7 in 2025Inovio Pharmaceuticals, InSilo Pharma, Inc.: 4th of 5 in 2019Silo Pharma, Inc.: 4th of 5 in 2020Silo Pharma, Inc.: 6th of 7 in 2022Silo Pharma, Inc.: 4th of 5 in 2023Silo Pharma, Inc.: 4th of 4 in 2024Silo Pharma, Inc.: 6th of 7 in 2025Silo Pharma, Inc.Ainos, Inc.: 4th of 4 in 2017Ainos, Inc.: 4th of 4 in 2018Ainos, Inc.: 5th of 5 in 2019Ainos, Inc.: 5th of 5 in 2020Ainos, Inc.: 3rd of 4 in 2021Ainos, Inc.: 2nd of 7 in 2022Ainos, Inc.: 3rd of 5 in 2023Ainos, Inc.: 2nd of 7 in 2025Ainos, Inc.BullFrog AI Holdings, Inc.: 7th of 7 in 2022BullFrog AI Holdings, Inc.: 5th of 5 in 2023BullFrog AI Holdings, Inc.: 2nd of 7 in 2025BullFrog AI Holdings, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearFutureWorldActinium Pharmaceuticals, Inc.AIM ImmunoTech Inc.iBio, Inc.Inovio Pharmaceuticals, Inc.Silo Pharma, Inc.Ainos, Inc.BullFrog AI Holdings, Inc.
2026———$0 MSEC————
2025—$0 MSEC4th$0 MSEC4th$0 MSEC1st$0 MSEC6th$0 MSEC6th$0 MSEC2nd$0 MSEC2nd
2024——$0 MSEC3rd$0 MSEC1st$0 MSEC1st$0 MSEC4th——
2023——$0 MSEC2nd—$1 MSEC1st$0 MSEC4th$0 MSEC3rd$0 MSEC5th
2022—$1 MSEC4th$0 MSEC5th$2 MSEC3rd$10 MSEC1st$0 MSEC6th$4 MSEC2nd$0 MSEC7th
2021—$1 MSEC2nd$0 MSEC4th$2 MSEC1st——$1 MSEC3rd—
2020——$0 MSEC3rd$2 MSEC2nd$7 MSEC1st$0 MSEC4th$0 MSEC5th—
2019——$0 MSEC3rd$2 MSEC2nd$4 MSEC1st$0 MSEC4th$0 MSEC5th—
2018——$0 MSEC3rd$0 MSEC2nd$30 MSEC1st—$0 MSEC4th—
2017——$0 MSEC2nd$0 MSEC3rd$42 MSEC1st—$0 MSEC4th—
2016——$0 MSEC3rd$1 MSEC2nd$35 MSEC1st———
2015——$0 MSEC3rd$2 MSEC2nd$41 MSEC1st———

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of FutureWorld#

Companies of the same industry, within a hundred times its size (latest annual revenue), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Actinium Pharmaceuticals, Inc.ATNM · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $48 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • AIM ImmunoTech Inc.AIM · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $6 M (Oct 27, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • iBio, Inc.IBIO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $59 M (Oct 9, 2026) · revenue $0 M (year to June 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Inovio Pharmaceuticals, Inc.INO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $144 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Silo Pharma, Inc.SILO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $3 M (Oct 5, 2026) · revenue $0 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Ainos, Inc.AIMD · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $6 M (Oct 26, 2026) · revenue $0 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • BullFrog AI Holdings, Inc.BFRG · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $9 M (Oct 29, 2026) · revenue $0 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Serina Therapeutics, Inc.SER · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $50 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    + Add
  • VivoSim Labs, INC.VIVS · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $3 M (Oct 20, 2026) · revenue $0 M (year to March 2026)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    + Add
  • Connect Biopharma Holdings LimitedCNTB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $54 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Avalo Therapeutics, Inc.AVTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $430 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Zivo Bioscience Inc.ZIVO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2024)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.